Clarivate Plc
Q4 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: −6.15%.
Did CLVT Beat Earnings? Q4 2025 Results
Clarivate delivered a clean beat to close out 2025, posting Q4 adjusted diluted EPS of $0.20 against a consensus estimate of $0.17, a 20.63% positive surprise, while revenue of $617.00 million edged past the $604.77 million consensus by 2.02%. The headline revenue decline of 6.9% year-over-year, from $663.00 million in Q4 2024, reflects deliberate portfolio pruning through divestitures rather than organic deterioration, with underlying organic revenues slipping just 1.2% and subscription revenues actually growing 1.0%. Perhaps the most consequential development accompanying the results was Clarivate's announcement that it is actively pursuing a sale of its Life Sciences & Healthcare segment, with Morgan Stanley advising on a process already drawing interested parties, a move that would sharpen the company's focus on its Academia & Government and Intellectual Property franchises. For 2026, management guided to revenues of $2.30 billion to $2.42 billion and adjusted diluted EPS of $0.70 to $0.80, projecting roughly 200 basis points of margin expansion as the company bets that strategic focus and a growing suite of AI-driven products will rebuild the growth profile investors have long awaited.
- Value Creation Plan driving improved sales execution, business model refinement, and investment in proprietary assets
- Organic subscription revenue growth of 1.0% in Q4 driven by new sales, improved retention and pricing actions
- Organic recurring revenue mix improved 800 basis points to 88% of total revenue
- Organic ACV grew 1.8% compared to prior year, driven by improved product pricing
- Disciplined capital expenditure management and lower interest/tax expenses improved free cash flow
“In 2025, Clarivate achieved significant innovation and growth. We advanced our Value Creation Plan by refining our business model, enhancing sales execution, and investing in proprietary assets while developing Agentic AI capabilities throughout our portfolio. These efforts have strengthened both our operational and financial standing and improved our revenue composition through the broader adoption of subscription-based services. As a result, we realized nearly 2% organic ACV growth, increased recurring organic revenue, and stronger free cash flow conversion, all while meeting our full-year financial guidance for 2025.”
Clarivate CEO, on the earnings call
Forward Guidance & Outlook
For full year 2026, Clarivate projects: Organic ACV growth of 2.0% to 3.0%; Recurring organic revenue growth of 0.75% to 2.25%; Total revenues of $2.30B to $2.42B (decline due entirely to strategic disposals); Adjusted EBITDA of $980M to $1.04B with margins of 42.0% to 43.5% (approximately 200 basis point expansion); Adjusted diluted EPS of $0.70 to $0.80 based on approximately 650 million diluted shares; Free cash flow of $365M to $435M (roughly 10% growth at midpoint). The company expects 2026 to be the final year of revenue decline from disposals. Revenue decline will be disproportionately concentrated in Q2-Q3. The company plans to favor deleveraging in deployment of remaining free cash flow after a $100M January 2026 debt repayment. Guidance excludes the potential sale of the LS&H business.
CLVT YoY Financials
CLVT Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.